Parnassus Investments
Parnassus Endeavor Fund
Parnassus Endeavor Fund Biomarin Pharmaceutical Inc stake
total: 118
Parnassus Endeavor Fund BMRN trades
- Total transactions:
- 3
- New positions:
- 1
- Sold out:
- 1
- Reduced:
- 1
- Held since:
- 2021 Q4
- Held for:
- 9 quarters
- Latest activity:
- 2024 Q1
According to 2026 Q2 report, Parnassus Endeavor Fund doesn't hold any Biomarin Pharmaceutical Inc (BMRN) shares. To date, the estimated cost basis is nearly $88.35 for "buy" trades and estimated average "sell" price is $97.94. Parnassus Endeavor Fund first purchased BMRN in 2021 Q4, initially acquiring about 1.06M shares. Since the initial investment in Biomarin Pharmaceutical Inc (BMRN), Parnassus Endeavor Fund has made 2 more transactions.
When did Parnassus Endeavor Fund sell Biomarin Pharmaceutical Inc (BMRN)?
Parnassus Endeavor Fund sold off the entire Biomarin Pharmaceutical Inc (BMRN) position in 2024 Q1.
When did Parnassus Endeavor Fund buy Biomarin Pharmaceutical Inc (BMRN)?
Parnassus Endeavor Fund first invested in Biomarin Pharmaceutical Inc (BMRN) in 2021 Q4 at the reported quarter-end price of $88.35 per share.
What's the cost basis of Parnassus Endeavor Fund's BMRN stake?
The estimated cost basis for Biomarin Pharmaceutical Inc (BMRN) stake is around $88.35 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $88.35
- Weighted AVG sell price:
- $97.94
Parnassus Endeavor Fund's historical trades in Biomarin Pharmaceutical Inc
3 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2024 Q1
|
0.00%
|
0
|
$96.42
|
|
-100% (-832,295)
|
-1.63%
|
|
2022 Q4
|
1.87%
|
832,295
|
$103.49
|
$86,134,210
|
-21.47% (-227,551)
|
-0.57%
|
|
2021 Q4
|
1.73%
|
1,059,846
|
$88.35
|
$93,637,394
|
new
|
+1.73%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.